Skyrizi Beats Stelara in Several Key Factors in Head-to-Head Comparison Trial
![Skyrizi Beats Stelara in Several Key Factors in Head-to-Head Comparison Trial](https://crohnsfighters.com/wp-content/uploads/2023/03/CROHNSFIGHTERS.COM__GLOBE_LOGO_MICHAELJANNICELLI_-1000x640.png)
AbbVie’s SKYRIZI® (risankizumab) Met All Primary and Secondary Endpoints Versus Stelara® (ustekinumab) in Head-to-Head Study in Crohn’s Disease
www.prnewswire.com